•
Apr 28, 2023

Medtronic Q4 2023 Earnings Report

Medtronic's Q4 2023 earnings exceeded expectations with broad-based strength across the company, driven by procedure volume recovery, supply improvements, and innovative product introductions.

Key Takeaways

Medtronic reported a strong finish to fiscal year 2023, with Q4 revenue of $8.5 billion, a 5.6% increase as reported and organic. GAAP diluted EPS was $0.88, a 20% decrease, while non-GAAP diluted EPS was $1.57, a 3% increase. The company issued FY24 guidance, projecting organic revenue growth in the range of 4.0% to 4.5% and non-GAAP EPS in the range of $5.00 to $5.10.

Q4 revenue of $8.5 billion increased 5.6% as reported and organic, ahead of expectations.

Q4 GAAP diluted EPS of $0.88 decreased 20%; non-GAAP diluted EPS of $1.57 increased 3% in the quarter, ahead of expectations.

Q4 revenue growth acceleration was broad-based, driven by procedure volume recovery, supply improvements, and innovative product introductions.

Strength in international markets in Q4, with high-single digit organic growth in non-U.S. developed markets and low-double digit organic growth in emerging markets.

Total Revenue
$8.54B
Previous year: $8.09B
+5.6%
EPS
$1.57
Previous year: $1.52
+3.3%
Gross Profit
$5.56B
Previous year: $5.09B
+9.3%
Cash and Equivalents
$1.54B
Previous year: $3.71B
-58.5%
Free Cash Flow
$2.08B
Previous year: $1.67B
+24.8%
Total Assets
$90.9B
Previous year: $91B
+-0.0%

Medtronic

Medtronic

Medtronic Revenue by Segment

Medtronic Revenue by Geographic Location

Forward Guidance

Medtronic is guiding to fiscal year 2024 organic revenue growth in the range of 4.0% to 4.5%, which excludes the impact of foreign currency and revenue related to certain businesses that will be reported as Other going forward. If foreign currency exchange rates as of the beginning of May hold, fiscal year 2024 revenue would be positively affected by approximately $110 million to $210 million from foreign currency. The company is guiding to fiscal year 2024 non-GAAP EPS in the range of $5.00 to $5.10, including an estimated 6% unfavorable impact from foreign currency exchange rates at the beginning of May.

Positive Outlook

  • Procedure recovery in many markets
  • Improving product availability
  • Strong competitive positions across businesses
  • Many new, innovative products coming to market
  • Taking measures to reduce costs across the company

Challenges Ahead

  • Impact from macro factors like inflation
  • Currency impact to earnings
  • Estimated 6% unfavorable impact from foreign currency exchange rates at the beginning of May.
  • Excludes the impact of foreign currency
  • Excludes revenue related to certain businesses that will be reported as Other going forward.

Revenue & Expenses

Visualization of income flow from segment revenue to net income